Skip to content
AnalystLens

Walmart Inc. 8-K Report, Regulation FD Disclosure (Oct 18, 2024)

Reports
Regulation FD·Exhibits & Filings
Filing Date
Filed October 18, 2024
Period End
October 18, 2024
Security
WMT
In the record · 2016–202610-K1110-Q328-K158

WMT filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 158 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · May ’18May ’18
  2. Leadership change8-K · Apr ’22Apr ’22
  3. Leadership change8-K · Jan ’26Jan ’26

Summary

Summary of the 8-K filed October 18, 2024. Cited figures are marked; the original filing is the authoritative source.

On October 18, 2024, Walmart disclosed a proposed settlement of three shareholder derivative lawsuits (Ontario Action, Abt, and Nguyen) that alleged its directors and officers breached fiduciary duties by failing to adequately oversee the distribution and dispensing of prescription opioids.

The settlement, which requires Delaware Court of Chancery approval, would have insurance carriers pay Walmart $123 milliona, less any attorneys' fees and litigation expenses awarded to plaintiffs' counsel. Walmart would also maintain certain corporate governance practices for at least five years. The settlement includes no admission of liability, and the defendants deny any wrongdoing.

The settlement follows roughly four years of litigation, including a Special Litigation Committee investigation formed in May 2023 that reviewed over 400,000 documents and interviewed 40 witnesses. The parties reached the agreement after a mediation process led by Judge Layn Phillips, with the mediator's settlement recommendation accepted on September 11, 2024. The Court scheduled a Settlement Fairness Hearing for December 20, 2024, and objections were due by December 5, 2024.

For investors, the financial impact is modest and largely non-operational: the $123 millionb recovery is paid to Walmart rather than to shareholders, and the company's capital position is not materially affected. The more significant takeaway is that the case closes a long-running governance and legal overhang tied to the opioid litigation, though the settlement's approval remains subject to court review.

Key Highlights

  1. Proposed settlement resolves three derivative actions tied to opioid distribution and dispensing oversight, subject to Delaware Court of Chancery approval
  2. Insurance carriers would pay Walmart $123 million, less any court-awarded attorneys' fees and litigation expenses; plaintiffs' counsel intends to seek fees up to 20% of the settlement fund plus up to $600,000 in expenses
  3. Walmart would maintain certain corporate governance practices for at least five years, to be implemented within 30 days after the effective date
  4. Settlement contains no admission of liability, and all defendants deny wrongdoing
  5. Special Litigation Committee, formed May 2023, reviewed over 400,000 documents and interviewed 40 witnesses before the mediated agreement
  6. Settlement Fairness Hearing scheduled for December 20, 2024; written objections due December 5, 2024
  7. No direct payment to individual shareholders; no proof-of-claim process, and the cash recovery goes entirely to the company

Frequently Asked Questions

  1. How much money will Walmart receive from the settlement?

    Walmart would receive $123 million, paid by the directors-and-officers insurance carriers into an escrow account. That amount is reduced by any attorneys' fees and litigation expenses the Court awards to plaintiffs' counsel, and it is subject to applicable taxes. Plaintiffs' counsel is seeking fees of up to 20% of the settlement fund, net of expenses, plus up to $600,000 in litigation expenses.

  2. Do individual Walmart shareholders receive any payment?

    No. Because these are derivative actions brought on behalf of Walmart, the recovery goes to the company. The notice states there is no proof-of-claim form and shareholders are not required to take any action, although current shareholders may object to the settlement or the fee request.

  3. Does the settlement admit wrongdoing by Walmart or its directors?

    No. The settlement expressly includes no admission of liability, and the defendants deny any wrongdoing, stating they complied with their statutory and fiduciary duties. The settlement was entered to avoid the cost, disruption, and uncertainty of continued litigation.

  4. What corporate governance changes are part of the settlement?

    Walmart agreed to implement the corporate governance practices set out in Exhibit E to the Stipulation no later than 30 days after the effective date, and to maintain them for at least five years. The specific terms are in the Stipulation, which was posted on the company's investor relations website and is not summarized in the 8-K itself.

  5. What happens next, and what could prevent the settlement from taking effect?

    The Court must hold a Settlement Fairness Hearing on December 20, 2024, to determine whether the settlement is fair, reasonable, and adequate and whether to approve the attorneys' fee request. The settlement is conditioned on the Court's approval, the federal derivative actions being dismissed with prejudice, and the judgment becoming final. Either side may terminate the settlement if the Court refuses approval or if the judgment is later vacated or reversed.